Claims
- 1. An IL-16 antagonist peptide.
- 2. An IL-16 antagonist peptide consisting of a sequence selected from the group consisting of RRKS (SEQ ID NO:2), RRTS (SEQ ID NO:3), KRKS (SEQ ID NO:4), RRAS (SEQ ID NO:5), RRKA (SEQ ID NO:6) and RRTA (SEQ ID NO:7).
- 3. An IL-16 antagonist peptide consisting of a sequence selected from the group consisting of RRKSLQ (SEQ ID NO:17), RRTSLQ (SEQ ID NO:18), RRKSCM (SEQ ID NO:19), KRKSMQ (SEQ ID NO:20), RRASLQ (SEQ ID NO:21), RRKALQ (SEQ ID NO:22) and RRTALQ (SEQ ID NO:23).
- 4. An IL-16 antagonist peptide consisting of a sequence selected from the group consisting of RRKSLQSK (SEQ ID NO: 24), RRTSLQCK (SEQ ID NO:25), RRKSLQPK (SEQ ID NO:26), RRKSCMSK (SEQ ID NO:27), KRKSMQSK (SEQ ID NO:28), RRASLQSK (SEQ ID NO:29), RRKALQSK (SEQ ID NO:30), RRTALQCK (SEQ ID NO:31) and RRASLQCK (SEQ ID NO:32).
- 5. An IL-16 antagonist peptide consisting of a sequence selected from the group consisting of RRTSLQCKQTTASADS (SEQ ID NO:34), RRASLQSKETTAAGDS (SEQ ID NO:35), RRKALQSKETTAAGDS (SEQ ID NO:36), RRTALQCKQTTASADS (SEQ ID NO:37) and RRASLQCKQTTASADS (SEQ ID NO:38).
- 6. An IL-16 antagonist peptide comprising Xaa0RXaa1Xaa2 (SEQ ID NO:1), wherein Xaa0 is Arg or Lys, and Xaa1 and Xaa2.are any amino acids.
- 7. The IL-16 antagonist peptide of claim 6, wherein Xaa1 is selected from Lys, Thr, or Ala; and Xaa2.is selected from Serine or Ala.
- 8. The IL-16 antagonist peptide of claim 6, wherein Xaa0 is Arg.
- 9. The IL-16 antagonist peptide of claim 8, wherein Xaa1 is selected from Lys, Thr, or Ala; and Xaa2.is Ser or Ala.
- 10. The IL-16 antagonist peptide of claim 6, wherein Xaa0 is Lys.
- 11. The IL-16 antagonist peptide of claim 10, wherein Xaa1 is selected from Lys, Thr, or Ala; and Xaa2.is Ser or Ala.
- 12. The IL-16 antagonist peptide of claim 8 or 10, wherein the tetrameric sequence coincides with the native sequence of a mammalian IL-16.
- 13. An IL-16 antagonist peptide comprising a sequence selected from the group consisting of RRKS (SEQ ID NO:2), RRTS (SEQ ID NO:3), KRKS (SEQ ID NO:4), RRAS (SEQ ID NO:5), RRKA (SEQ ID NO:6) and RRTA (SEQ ID NO:7).
- 14. An IL-16 antagonist peptide comprising Xaa1Xaa2Xaa0R (SEQ ID NO:8), wherein Xaa0 is Arg or Lys, and Xaa1 and Xaa2.are any amino acids.
- 15. The IL-16 antagonist peptide of claim 14, wherein Xaa1 is Val and Xaa2.is Ile or Leu.
- 16. The IL-16 antagonist peptide of claim 14, wherein Xaa0 is Arg.
- 17. The IL-16 antagonist peptide of claim 16, wherein Xaa1 is Val and Xaa2.is Ile or Leu.
- 18. The IL-16 antagonist peptide of claim 14, wherein Xaa0 is Lys.
- 19. The IL-16 antagonist peptide of claim 18, wherein Xaa1 is Val and Xaa2.is Leu or Ile.
- 20. The IL-16 antagonist peptide of claim 16 or 18, wherein the tetrameric sequence coincides with the native sequence of a mammalian IL-16.
- 21. An IL-16 antagonist peptide comprising a sequence selected from the group consisting of VIRR (SEQ ID NO:9), VLRR (SEQ ID NO:10) and VIKR (SEQ ID NO:11).
- 22. An IL-16 antagonist peptide comprising Xaa1Xaa0RXaa2 (SEQ ID NO:12), wherein Xaa0 is Arg or Lys, and Xaa1 and Xaa2.are any amino acids.
- 23. The IL-16 antagonist peptide of claim 22, wherein Xaa1 is Ile or Leu and Xaa2.is Lys, Thr or Ala.
- 24. The IL-16 antagonist peptide of claim 22, wherein Xaa0 is Arg.
- 25. The IL-16 antagonist peptide of claim 24, wherein Xaa1 is selected from Ile or Leu and Xaa2.is Lys, Thr or Ala.
- 26. The IL-16 antagonist peptide of claim 22, wherein Xaa0 is Lys.
- 27. The IL-16 antagonist peptide of claim 26, wherein Xaa1 is selected from Leu or Ileu; and Xaa2.is Lys, Thr or Ala.
- 28. The IL-16 antagonist peptide of claim 24 or 26, wherein the tetrameric sequence coincides with the native sequence of a mammalian IL-16.
- 29. An IL-16 antagonist peptide comprising a sequence selected from the group consisting of IRRK (SEQ ID NO:13), IRRT (SEQ ID NO:14), LRRK (SEQ ID NO:15) and IKRK (SEQ ID NO:16).
- 30. An IL-16 antagonist peptide comprising a sequence selected from the group consisting of RRKSLQ (SEQ ID NO:17), RRTSLQ (SEQ ID NO:18), RRKSCM (SEQ ID NO:19), KRKSMQ (SEQ ID NO:20), RRASLQ (SEQ ID NO:21), RRKALQ (SEQ ID NO:22) and RRTALQ (SEQ ID NO:23).
- 31. An IL-16 antagonist peptide comprising a sequence selected from the group consisting of RRKSLQSK (SEQ ID NO:24), RRTSLQCK (SEQ ID NO:25), RRKSLQPK (SEQ ID NO:26), RRKSCMSK (SEQ ID NO:27), KRKSMQSK (SEQ ID NO:28), RRASLQSK (SEQ ID NO:29), RRKALQSK (SEQ ID NO:30), RRTALQCK (SEQ ID NO:31) and RRASLQCK (SEQ ID NO:32).
- 32. An IL-16 antagonist peptide comprising a sequence selected from the group consisting of RRTSLQCKQTTASADS (SEQ ID NO:34), RRASLQSKETTAAGDS (SEQ ID NO:35), RRKALQSKETTAAGDS (SEQ ID NO:36), RRTALQCKQTTASADS (SEQ ID NO:37) and RRASLQCKQTTASADS (SEQ ID NO:38).
- 33. An isolated nucleic acid molecule coding for any one of the peptide of claims 1-4, 6, 14 or 22.
- 34. An antibody raised against the peptide of any one of claims 1-4, 6, 14 or 22.
- 35. A pharmaceutical composition comprising the peptide of any of claims 1-4, 6, 14 or 22 and a pharmaceutically acceptable carrier.
- 36. A pharmaceutical composition comprising the antibody of claim 34.
- 37. A method of treating an IL-16 mediated disorder in a subject, comprising administering to the subject a therapeutically effective amount of the peptide of any of claims 1-4, 6, 14 or 22 and a pharmaceutically acceptable carrier.
- 38. The method of claim 37, wherein said IL-16 mediated disorder is an inflammatory disease selected from asthma, rheumatoid arthritis, inflammatory bowel disease, Graves' disease, multiple sclerosis, lupus or bullous pemphigoid.
- 39. The method of claim 38, further comprising simultaneously administering an anti-inflammatory agent selected from an anti-CD4 antibody, an anti-TNFα antibody, NSAIDS, steroids, cyclosporin-A or a cytotoxic drug.
- 40. An IL-16 antagonist.
- 41. A pharmaceutical composition comprising an IL-16 antagonist and a pharmaceutically acceptable carrier.
- 42. A method of treating an IL-16 mediated disorder comprising blocking the interaction of IL-16 with an IL-16 receptor by the administration of an IL-16 antagonist.
Government Interests
[0001] This invention was made in the course of work under grant HL32802 sponsored in part by the National Institute of Health.
Continuations (1)
|
Number |
Date |
Country |
Parent |
09368630 |
Aug 1999 |
US |
Child |
10358627 |
Feb 2003 |
US |